Evercore ISI cuts Medline stock price target on tariff impact

Evercore ISI cut Medline’s price target to $44 from $55 but maintained an Outperform rating after Q3 organic sales rose 10.5%, 1.8% above consensus, and EBITDA excluding refunds reached about $879 million, modestly ahead of expectations. Maintained Q4 guidance implies EBITDA 3.5% below Street estimates at the midpoint; fiscal 2026 EBITDA estimates rose to $3.71 billion from $3.64 billion, while fiscal 2027 estimates fell to $3.45 billion from $3.79 billion as tariff costs and the expiration of refunds weigh on reported results. The article also reports Q3 revenue of $7.9 billion, adjusted EPS of $0.44, adjusted EBITDA of $1 billion, a raised full-year organic sales outlook, and a new share repurchase plan.

Analysis

Setup: The key issue is earnings quality, not demand: strong organic growth coexists with a weaker fourth-quarter EBITDA midpoint and a materially lower FY27 estimate. Inventory-cost timing and tariff-refund roll-off make reported comparisons noisy; the investment question is whether pricing and operational savings can offset tariffs, oil, and reinvestment without slowing growth. A high valuation leaves limited room for execution slippage.

Second-order effects: Cost pass-through may lag the rise in input costs, creating near-term margin pressure even if customers ultimately absorb higher prices. Medline’s scale could help purchasing and customer retention, but competitors such as Cardinal Health, McKesson, and Owens & Minor may face similar cost and repricing dynamics; relative performance will depend on their ability to pass through costs and protect service levels, not just headline sales growth. Buybacks may support per-share results but do not resolve the EBITDA bridge.

Horizon and contrarian view: Over days, the estimate cut and below-Street Q4 implication may outweigh the Q3 beat. Over 1–3 months, watch realized cost pass-through, inventory costs, and guidance revisions. Over 6–18 months, the bull case is that core growth and restructuring savings absorb temporary headwinds; the bear case is that tariff/oil pressure and refund normalization persist. The market may be overemphasizing reported FY27 decline, but the elevated valuation makes waiting for proof preferable to buying the growth narrative. Treat differing EBITDA figures in the article as definition/scope differences to reconcile, not as directly comparable measures.

Key Decisions for Investors

• Avoid chasing the Q3 beat; keep MDLN at neutral/underweight until management demonstrates that pricing and savings are offsetting input costs. The revised FY27 outlook and Q4 gap are nearer-term price risks.
• Watch next-quarter gross-margin/EBITDA commentary, realized repricing, tariff and oil assumptions, and whether core growth holds. A further estimate reduction or weaker guidance would falsify the normalization thesis; sustained margin recovery alongside growth would weaken the cautious view.
• No immediate options trade: the article supplies no volatility or event-pricing data. Reassess after the next results and reconcile EBITDA definitions, tariff-refund treatment, and the timing of higher-cost inventory flowing through cost of goods sold.